Credit Suisse Ag Avalo Therapeutics, Inc. Transaction History

Credit Suisse Ag

  • $101 Billion
  • Q1 2024

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 12, 2022
BUY
$3.0 - $10.45 $99 - $344
33 New
33 $0

Others Institutions Holding AVTX

# of Institutions
1
Shares Held
34.6K
Call Options Held
0
Put Options Held
0
View Full List

About Avalo Therapeutics, Inc.

AVTX Quotes by TradingView
  • Ticker AVTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 9,414,100
  • Market Cap $118M
  • Description
  • Avalo Therapeutics, Inc., a clinical-stage precision medicine company, discovers, develops, and commercializes targeted therapeutics for patients with unmet clinical need in immunology, immuno-oncology, and rare genetic diseases. It develops AVTX-002, a fully human anti-LIGHT monoclonal antibody, which is under Phase II clinical trial for the tr...
More about AVTX
Track This Portfolio

Track Credit Suisse Ag Portfolio

Follow Credit Suisse Ag and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Credit Suisse Ag, based on Form 13F filings with the SEC.

News

Stay updated on Credit Suisse Ag with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email